Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?

Translated title of the contribution: Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?

Ariana P. Vargas Delgado, Juan Antonio Requena Ibañez, Carlos G. Santos-Gallego, Juan Jose Badimon

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

The sodium-glucose co-transporter 2 inhibitors (SGLT2i) were first conceived to treat type 2 diabetes due to their hypoglycaemic effect. However, due to an increasing number of studies, SGLT2i are changing the way we treat, and understand, diabetes, and cardiovascular risk, in general. The EMPA-REG OUTCOME clinical trial, in 2015, showed for the first time that empagliflozine - a glucose lowering agent - lowers the risk of death from cardiovascular causes and death from any cause. Also, this SGLT2i lowered hospital admission for heart failure and delayed renal function worsening. From then on, other clinical trials with SGLT2i such as CANVAS (canagliflozin) and DECLARE-TIMI-58 (dapagliflozin) confirmed these positive effects. With a proven and non-related glucose-lowering effect on heart failure, overall death, cardiovascular death, and renal function, SGLT2i stands out among the rest of anti-diabetic drugs. Since its role in treating patients with heart failure and type 2 diabetes has been undoubtedly established, new studies are paving the way for non-diabetic patients as well. A potential paradigm shift is being witnessed and, probably, the dawn of a new field, cardio-endocrinology, which involves new and far-reaching pharmacological agents.

Translated title of the contributionAre the antidiabetic SGLT2 inhibitors a cardiovascular treatment?
Original languageEnglish
Pages (from-to)33-40
Number of pages8
JournalClinica e Investigacion en Arteriosclerosis
Volume33
Issue number1
DOIs
StatePublished - 1 Jan 2021

Keywords

  • Cardiovascular risk
  • Diabetes
  • Heart failure

Fingerprint

Dive into the research topics of 'Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?'. Together they form a unique fingerprint.

Cite this